Rivaroxaban

( DrugBank: Rivaroxaban / KEGG DRUG: Rivaroxaban )


5 diseases
IDDisease name (Link within this page)Number of trials
46Malignant rheumatoid arthritis2
49Systemic lupus erythematosus3
91Budd-Chiari syndrome2
IDDisease name (Link within this page)Number of trials
210Single Ventricle4
271Ankylosing spondylitis1

46. Malignant rheumatoid arthritis


Clinical trials : 4,543Drugs : 2,251 - (DrugBank : 390) / Drug target genes : 198 - Drug target pathways : 232 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries

49. Systemic lupus erythematosus


Clinical trials : 1,227Drugs : 752 - (DrugBank : 175) / Drug target genes : 130 - Drug target pathways : 207 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries

91. Budd-Chiari syndrome


Clinical trials : 3Drugs : 4 - (DrugBank : 3) / Drug target genes : 4 - Drug target pathways : 12 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries

210. Single Ventricle


Clinical trials : 56Drugs : 49 - (DrugBank : 25) / Drug target genes : 35 - Drug target pathways : 77 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries

271. Ankylosing spondylitis


Clinical trials : 603Drugs : 302 - (DrugBank : 69) / Drug target genes : 40 - Drug target pathways : 146 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries